PharmaEssentia Gets S&C’s Advice on $462 Million GDS Offering
PharmaEssentia Corp., a prominent biopharmaceutical business, completed its $462.7 million global depositary share (GDS) sale on April 18, making it Taiwan’s largest overseas biotech transaction. GDSs are traded on the Luxembourg Stock Exchange’s Euro MTF Market.
![Pasted image 0](https://lawfirmrankingsreport.com/wp-content/uploads/pasted-image-0-30.png)
Ching-Yang Lin, Partner
PharmaEssentia produces and distributes medicinal treatments for MPN and other haematology and oncology illnesses. BESREMi®, the company’s principal medication, is approved for polycythemia vera treatment in 29 countries, including the US, EU, and Japan.
![Pasted image 0](https://lawfirmrankingsreport.com/wp-content/uploads/pasted-image-0-36.png)
Jeffrey D. Hochberg, Partner
The S&C team advising Citigroup, J.P. Morgan, Morgan Stanley, Macquarie, UBS, and Yuanta as first GDS purchasers included Ching-Yang Lin, Stephen Pang, Hanzhi Wang, Henry Wong, and Hester Choi. Tax advisors were Jeffrey Hochberg, Saul Brander, and Tristan Hood. 40 Act advice came from Frederick Wertheim.
![Pasted image 0](https://lawfirmrankingsreport.com/wp-content/uploads/pasted-image-0-44.png)
Saul Brander, Special Counsel
For detailed information, as well as the picture copyright, please see the law firm’s original article here: S&C Advises PharmaEssentia on $462 Million GDS Offering